Martin Ziegler

Dr. Martin Ziegler

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Henrik FaatzHenrik Faatz
Henrik Faatz
KRKai Rothaus
Kai Rothaus
MZMartin Ziegler
Martin Ziegler
MBMarius Book
Marius Book
BHBritta Heimes-Bussmann
Britta Heimes-Bussmann
ALAlbrecht Lommatzsch
Albrecht Lommatzsch
Background: The clinical appearance of macular neovascularization (MNV) in age-related macular degeneration (nAMD) varies widely, but so far, this has had no relevance in terms of therapeutic approaches or prognosis. Therefore, our purpose was to investigate if and which differences exist in the vascular architecture of MNV and to quantify them. Methods: In 90 patients with newly diagnosed nAMD, MNV was identified by means of optical coherence tomography angiography (OCTA), and automated quantitative vascular analysis was carried out. The analyzed vascular parameters were area, flow, fractal dimension (FD), total vascular length (sumL), number of vascular nodes (numN), flow, and average vessel caliber (avgW). The current classification of MNVs divides them according to their localization into type 1 (grown from the choroid below the RPE), type 2 (grown from the choroid through RPE), and type 3 (grown from the retina toward the RPE). We compared the analyzed vascular parameters of each of the three MNV types. Kruskal–Wallis test was applied, Dunn test was performed for post hoc analysis, and for pairwise comparison, p-values were adjusted using Bonferroni comparison. Results: Regarding the MNV area, there was no significant difference between types 1 and 2, but type 3 was significantly smaller than types 1 and 2 (p < 0.00001). For FD, types 1 and 2 did not differ significantly, but again, type 3 was lower than type 1 and 2 (p < 0.00001). The numN were significantly higher in types 1 and 3 than in 2 (p < 0.005), but not between types 1 and 3. No significant differences were found between MNV types for flow. As for sumL, types 1 and 2 did not differ significantly, but type 3 was significantly lower than types 1 and 2 (p < 0.00001). For avgW, there was no significant difference between types 1 and 2 or between types 2 and 3, but type 3 was significantly larger than type 1 (p < 0.05). Conclusions OCTA yields detailed information on the vascular morphology of MNV in patients with nAMD and is able to show differences among types 1, 2, and 3. Especially comparing types 1 and 2 with type 3 reveals significant differences in area, FD, sumL, and numN. One explanation could be the similar pathogenesis of types 1 and 2 with their origin in the choroid and their growth towards the retinal pigment epithelium (RPE), whereas type 3 originates in the deep capillary plexus. Between types 1 and 2, however, only the numN differ significantly, which could be due to the fact that type 1 spreads horizontally below the RPE and, thus, display more vascular branching, while type 2 grows more vertically through the RPE and under the neurosensory retina. Detailed information about the pathologic vasculature is important for proper monitoring of the disease and to assess the efficacy of medication, especially with regard to new substances. This should be taken into consideration in future studies.

15 November 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Henrik FaatzHenrik Faatz
Henrik Faatz
KRKai Rothaus
Kai Rothaus
MZMartin Ziegler
Martin Ziegler
MBMarius Book
Marius Book
GGGeorg Georg
Georg Georg
ALAlbrecht Lommatzsch
Albrecht Lommatzsch
Introduction: Anti-VEGF therapy is an effective option for improving and stabilizing the vision in neovascular age-related macular degeneration (nAMD). However, the response to treatment is markedly heterogeneous. The aim of this study was therefore to analyze the vascular characteristics of type 1,2, and 3 macular neovascularizations (MNV) in order to identify biomarkers that predict treatment response, especially with regard to changes in intraretinal and subretinal fluid. Materials and Methods: Overall, 90 treatment-naive eyes with nAMD confirmed by optic coherence tomography (OCT), fluorescein angiography, and OCT angiography (OCTA) were included in this retrospective study. The MNV detected by OCTA were subjected to quantitative vascular analysis by binarization and skeletonization of the vessel using ImageJ. We determined their area, total vascular length (sumL), fractal dimension (FD), flow density, number of vascular nodes (numN), and average vascular diameter (avgW). The results were correlated with the treatment response to the initial three injections of anti-VEGF and the changes in intraretinal (IRF) and subretinal fluid (SRF) and the occurrence of pigment epithelial detachements (PED). Results: All patients found to have no subretinal or intraretinal fluid following the initial three injections of anti-VEGF showed a significantly smaller MNV area (p < 0.001), a lower sumL (p < 0.0005), and lesser FD (p < 0.005) before treatment than those who still exhibited signs of activity. These parameters also showed a significant influence in the separate analysis of persistent SRF (p < 0.005) and a persistent PED (p < 0.05), whereas we could not detect any influence on changes in IRF. The vascular parameters avgW, numN, and flow density showed no significant influence on SRF/IRF or PED changes. Conclusions: The size, the total vessel length, and the fractal dimension of MNV at baseline are predictors for the treatment response to anti-VEGF therapy. Therefore, particularly regarding the development of new classes of drugs, these parameters could yield new insights into treatment response.

22 December 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DPDaniel Pauleikhoff
Daniel Pauleikhoff
MGMarie-Luise Gunnemann
Marie-Luise Gunnemann
MZMartin Ziegler
Martin Ziegler
BHBritta Heimes-Bussmann
Britta Heimes-Bussmann
EBEike Bormann
Eike Bormann
LPLaurenz Pauleikhoff
Laurenz Pauleikhoff
Purpose: To analyze the morphological changes of macular neovascularization (MNV) in exudative neovascular age-related macular degeneration under long-term intravitreal anti-vascular endothelial growth factor (VEGF) therapy in a retrospective cohort study. Methods and patients: We evaluated 143 nAMD eyes of 94 patients (31 male, 63 female; initial age 55–97 y, mean age 75.9 ± 7.5 y), who started anti-VEGF therapy (IVAN pro re nata (PRN) protocol) between 2009–2018 and received ongoing therapy until the last recorded visit (mean follow-up 5.3 ± 2.9 y, range 1–14 y). The mean total number of injections was 33.3 ± 19.8 with 7.0 ± 2.3 injections/year. MNV size and, if present, associated complete retinal pigment epithelium (RPE) and outer retina atrophy (cRORA) size were measured on optical coherence tomography (OCT) volume scans at the initial visit and for each year of follow-up. MNV and cRORA were identified on B-scans and their respective borders were manually transposed onto the en-face near infrared image and measured in mm2. Results: MNV enlarged through follow-up, with a mean growth rate of 1.24 mm2 / year. The mean growth in MNV size was independent of initial MNV size, age, gender, MNV subtypes or number of injections per year. Nevertheless, a great interindividual variation in size and growth was observed. cRORA developed in association with increasing MNV size and its incidence increased linearly over follow-up. cRORA lesions also showed continuous growth by a rate of 1.22 mm2 / year. Conclusions: Despite frequent long-term anti-VEGF therapy, we observed ongoing MNV growth. This is consistent with the concept that the development of MNV may be a physiological biological repair mechanism to preserve RPE and photoreceptor function, provided hyperpermeability and fluid exudation are controlled. Whether recurring low VEGF levels or other factors are responsible for MNV growth remains controversial.

1 October 2020 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
Henrik FaatzHenrik Faatz
Henrik Faatz
KRKai Rothaus
Kai Rothaus
MZMartin Ziegler
Martin Ziegler
MBMarius Book
Marius Book
CLClaudia Lommatzsch
Claudia Lommatzsch
ALAlbrecht Lommatzsch
Albrecht Lommatzsch
Purpose: The aim of this study was to ascertain and quantify the differences between swept-source (SS) and spectral-domain (SD) optical coherence tomography angiography (OCTA) imaging of macular neovascularizations (MNV) in neovascular age-related macular degeneration (nAMD). Patients and Methods: SD-OCTA (RTVue Avanti) and SS-OCTA (PLEX® Elite 9000) were performed in 37 patients with MNV in nAMD. The MNV was delineated and the data were processed via ImageJ. The parameters MNV area, nodes per area, fractal dimension (FD), and flow density were analyzed using MatLab. Results: There was close agreement between the two devices regarding MNV area (ICCc 0.977, ICCa 0.977, R2 0.977), but only slight agreement regarding nodes per area (ICCa 0.008, ICCc 0.548, R2 0.51), FD (ICCa 0.425, ICCc 0.846, R2 0.96), and flow density (ICCa 0.451, ICCc 0.656, R2 0.65). The difference between the two devices was insignificant for MNV area (type 1: p=0.328; type 2: p=0.426; type 3: p=0.615), but significant for nodes per area (type 1: p=0.002; type 2: p=0.00001; type 3: p=0.003), FD (type 1: p< 0.00001; type 2: p< 0.00001; type 3: p=0.015) and flow density (type 1: p=0.0004; type 2: p=0.004; type 3: p=0.052). Conclusion: MNV area is closely comparable between devices using SS-OCTA and SD-OCTA imaging. However, the two methods differ significantly in their precise assessment of the vascular morphology (FD, flow density, nodes per area). Therefore, results obtained using different devices are not comparable and should not be amalgamated in clinical trials.

12 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MGMichael Grün
Michael Grün
KRKai Rothaus
Kai Rothaus
MZMartin Ziegler
Martin Ziegler
CLClemens Lange
Clemens Lange
ALAlbrecht Lommatzsch
Albrecht Lommatzsch
Henrik FaatzHenrik Faatz
Henrik Faatz
Background: Anti-Vascular Endothelial Growth Factor (VEGF) therapy is an effective therapy for improving and stabilizing the vision of patients with neovascular age-related macular degeneration (nAMD). However, the treatment requirements, particularly the number of intraocular injections, can vary significantly among patients. This study aimed to analyze the vascular characteristics of macular neovascularizations (MNVs) to identify potential biomarkers that could predict the required injection frequency throughout the disease course. Methods: In all patients, the initial diagnosis of nAMD was confirmed using optic coherence tomography (OCT), fluorescein angiography, and OCT angiography (OCTA). MNVs detected using OCTA were subjected to quantitative vascular analysis of their area, total vascular length (sumL), fractal dimension (FD), and flow density. These results were then correlated with the number of intravitreal anti-VEGF treatments administered during the first 3 years of treatment. Additionally, the relationship between the parameters and visual acuity progression was analyzed. Results: A total of 68 treatment-naïve eyes were included in the study, comprising 31 eyes with type 1 MNV, 19 eyes with type 2 MNV, and 18 eyes with type 3 MNV. The average MNV area at baseline was 1.11 mm2 ± 1.18 mm2, the mean total vascular length was 12.95 mm ± 14.24 mm, the mean fractal dimension was 1.26 ± 0.14, and the mean flow density was 41.19 ± 5.87. On average, patients in our cohort received 19.8 ± 8.5 intravitreal injections (IVIs). A significant correlation was found between the number of administered IVIs in the first 3 treatment years and the MNV area (p < 0.005), sumL (p < 0.005), and FD (p < 0.05), while no correlation was found with flow density. Additionally, there was no significant association between MNV type and treatment requirements, nor between MNV vascular architecture and visual acuity progression. Conclusions: The results suggest that the specific vascular structure of untreated MNV may serve as a predictor of long-term treatment demand. With the emergence of new drug classes and advancements in imaging techniques, these parameters could offer valuable insights for forecasting treatment requirements.

11 January 2026 in Physiologia
Verified
Journal Article
Open access
PDF file
MGMichael Grün
Michael Grün
KRKai Rothaus
Kai Rothaus
MZMartin Ziegler
Martin Ziegler
ABAlexander Beger
Alexander Beger
ALAlbrecht Lommatzsch
Albrecht Lommatzsch
Henrik FaatzHenrik Faatz
Henrik Faatz
Background: To investigate baseline MNV characteristics in Optical Coherence Tomography Angiography (OCTA) and its impact on therapeutic needs and visual acuity after 5 years in initially therapy-naïve eyes. Methods: A retrospective study of 43 therapy-naïve eyes with neovascular AMD (nAMD). OCTA was performed at baseline and all eyes were observed for 5 years. MNV architecture was characterized by area, total vessel length, flow density and fractal dimension. These variables were tested for correlation with the number of administered intravitreal injections (IVIs) and best-corrected visual outcome (BCVA) after 5 years of treatment. Results: Mean follow-up time was 4.97 ± 0.21 years. Area and total vessel length of MNVs were significantly associated with a higher number of administered IVIs after 5 years (p < 0.05), flow density significantly correlated with fewer IVIs (p < 0.05). Fractal dimension showed a tendency to more IVIs (p = 0.056) after 5 years. Flow density at baseline correlated with a better BCVA (p < 0.05). In contrast, MNV area size, total vessel length and fractal dimension did not show any correlation to BCVA after 5 years (p > 0.05). Conclusions: Specific features of MNV architecture such as area, total vessel length and flow density can predict long-term treatment requirement and visual outcome. Further studies using deep learning algorithms are necessary to explore the usage of these findings in daily practice.